• 2012.02
• PharmaEngine, Inc. announces initiation of a Global Phase 3 Study on PEP02/MM-398 (Nanoliposomal Irinotecan) with Metastatic Pancreatic Cancer, the first patient has been dosed.

• 2012.01
• >Phase 1 Study of Biweekly PEP02 in Metastatic Colorectal Cancer will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium.

• 2011.11
• >Poster Presentation of PEP02 at the 2011 AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics

• 2011.09
• >PharmaEngine, Inc. debut on Taiwan's emerging stock market on September 1, 2011

• 2011.07
• >US FDA grants orphan drug status to PEP02 (Merrimack Pharmaceuticals’ MM-398), for the treatment of pancreatic cancer

• 2011.07
• >PharmaEngine, Inc. approved by Taiwan Securities & Futures Bureau (SFB) for IPO.

• 2011.07
• >Orally Presented a pre-clinical study of PEP02 for four xenograft models in human lung tumors at 14th World Conference on Lung Cancer (WCLC) in Amsterdam, Netherlands.

• 2011.06
• >Presented a poster of phase II study of PEP02 for patients with gemcitabine-refractory metastatic pancreatic cancer at 2011 ASCO Annual Meeting

• 2011.05
• > PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan

• 2011.01
• > PharmaEngine Reports that PEP02 Met the Primary Endpoints in Phase II Studies in Gastric Cancer and Pancreatic Cancer